Dual-Label CTC Detection Resolves EpCAM Loss During EMT
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting circulating tumor cells (CTCs) face challenges in accurately determining metastasis and cancer progression due to the induction of epithelial-mesenchymal transition (EMT), which reduces EpCAM expression, making it difficult to detect highly malignant and metastatic CTCs, and the uncertainty in EMT induction rates among low-numbered CTCs complicates cancer staging.
Innovation Solution
A method involving fluorescently or luminescently labeled components specific to epithelial and mesenchymal cell markers, such as cytokeratin and vimentin, to quantify the EMT index using formulas like P=M/(E+M), allowing for accurate determination of cancer malignancy and progression by measuring the ratio of these markers in CTCs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If EpCAM antibody-based detection is used to identify CTCs, then epithelial CTCs can be detected, but highly malignant CTCs with induced EMT cannot be detected due to reduced EpCAM expression
Solution Approach 1:
The patent employs a dual-marker detection system that simultaneously targets both EpCAM (epithelial marker) and vimentin (mesenchymal marker). This multi-functional approach enables the detection system to identify both epithelial-type CTCs and mesenchymal-type CTCs, thereby achieving universality across different CTC phenotypes and resolving the limitation of EpCAM-only detection
Solution Approach 2:
The patent changes the detection parameters by introducing a second marker (vimentin) with different expression characteristics. Instead of relying solely on EpCAM expression levels, the system measures both EpCAM and vimentin expression to calculate an EMT index, allowing detection of CTCs across the spectrum of EMT induction states
2Measurement precision
If CTC detection is performed in highly concentrated blood cells, then CTCs can be identified, but count loss and sample contamination occur due to extremely low CTC concentration
Solution Approach 1:
The patent implements a feedback mechanism by calculating the EMT index based on the ratio of vimentin to EpCAM expression. This quantitative feedback allows for the identification and exclusion of non-CTC cells that may falsely express epithelial markers, thereby improving diagnostic reliability and preventing count loss from misidentification
Solution Approach 2:
The EMT index serves as an intermediary parameter that mediates between raw fluorescence intensity measurements and final CTC identification. By using this intermediate calculation, the system can distinguish true CTCs from contaminating cells more reliably, reducing both count loss and contamination errors
3Measurement precision
If EMT induction rate is used to determine cancer staging, then cancer progression can be assessed, but uncertainty in EMT induction rates among low-numbered CTCs complicates staging
Solution Approach 1:
The patent transforms the staging assessment from relying on absolute CTC counts to relying on the EMT index parameter. This parameter change allows meaningful cancer progression assessment even when CTC numbers are low, as the EMT index provides a normalized ratio that is independent of sample size
Solution Approach 2:
The patent performs preliminary calculation of the EMT index for each detected CTC before making staging determinations. This preliminary action on individual cell level aggregates to provide a robust overall assessment, reducing uncertainty even when the total number of CTCs is small
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables precise diagnosis of cancer metastasis, progression, and malignancy, facilitating the prediction of metastasis occurrence and monitoring of therapeutic effects by providing a reliable EMT index from CTC analysis.
Implementation Method 1
an epithelial cell-binding component which specifically binds to a marker molecule expressed on epithelial cells and is fluorescently-labeled or luminescent enzyme-labeled
Data Source
AI summary
The object of the present invention is to provide an evaluation method capable of accurately determining a metastasis of cancer, the stage of cancer progression, or the malignancy of cancer.The object can be solved by a method for detecting the degree of malignancy of each of the circulating tumor cells, characterized by the following steps: (a) bringing an epithelial cell-binding component, which specifically binds to a marker molecule expressed on epithelial cells and is fluorescently-labeled or luminescent enzyme-labeled, and a mesenchymal cell-binding component, which specifically binds to a marker molecule expressed on mesenchymal cells and is fluorescently-labeled or luminescent enzyme-labeled, into contact with a sample that possibly contains circulating tumor cells, (b) detecting a fluorescence signal or a luminescence signal of the epithelial cell-binding component and a fluorescence signal or a luminescence signal of the mesenchymal cell-binding component of each of the cells, and (c) determining the degree of epithelial-mesenchymal transition of circulating tumor cells based on the signal amount of the epithelial cell-binding component (E) and the signal amount of the mesenchymal cell-binding component (M).